JGC
LPCN icon

J. Goldman & Co’s Lipocine LPCN Stock Holding History

J. Goldman & Co’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42,170
Closed -$337K – 825
2026
Q1 		$337K Buy
+42,170
New +$367K 0.01% 552
2019
Q1 		– Sell
-14,025
Closed -$310K – 298
2018
Q4 		$310K Sell
14,025
-15,425
-52% -$358K 0.02% 216
2018
Q3 		$691K Sell
29,450
-12,609
-30% -$310K 0.05% 208
2018
Q2 		$930K Buy
+42,059
New +$1M 0.05% 260
2015
Q3 		– Sell
-4,412
Closed -$643K – 277
2015
Q2 		$643K Sell
4,412
-882
-17% -$109K 0.04% 200
2015
Q1 		$621K Buy
+5,294
New +$576K 0.04% 243

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

J. Goldman & Co's LPCN Position: Q2 2026 in Review

J. Goldman & Co sold out of Lipocine (LPCN) in Q2 2026, closing a stake of 42,170 shares — an estimated $337K sold.

J. Goldman & Co first reported a position in LPCN in Q1 2015 and held it in 6 quarters. The position peaked at $930K in Q2 2018. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • J. Goldman & Co reported no remaining Lipocine position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 42,170 Lipocine shares in Q2 2026, an estimated $337K.
  • J. Goldman & Co first reported a position in Lipocine in Q1 2015 and held it in 6 quarters.
  • J. Goldman & Co's Lipocine position peaked at $930K in Q2 2018.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.